Atara Biotherapeutics Inc. announced its first-quarter 2025 financial results, highlighting a significant turnaround in its financial performance. The company reported a net income of $38.0 million, a stark contrast to the net loss of $31.8 million recorded in the same period in 2024. This improvement is reflected in the earnings per share, which stood at $3.53 basic and $3.50 diluted for the first quarter of 2025, compared to a basic and diluted loss per share of $5.65 in the previous year. The company also revealed that its cash, cash equivalents, and short-term investments totaled $13.8 million as of March 31, 2025, down from $42.5 million at the end of 2024. Significant operational changes were also reported, with Atara transferring all manufacturing responsibilities to Pierre Fabre Laboratories for the development and commercialization of tabelecleucel worldwide. This strategic move is expected to reduce Atara's operating expenses by approximately 65% year-over-year by 2025. Additionally, Atara implemented a company-wide restructuring in May 2025, resulting in a 30% reduction in workforce, retaining essential personnel for the EBVALLOTM collaboration with Pierre Fabre Laboratories. The company has also entered an underwriting agreement expected to yield gross proceeds of $16 million, which will be used to fund ongoing activities for potential BLA approval.